Sales of oseltamivir in Norway prior to the emergence of oseltamivir resistant influenza A(H1N1) viruses in 2007-08

Virology Journal

Volumn 6, Issue , 2009, Pages

  Hauge, Siri H ^a,b   Blix, Hege S ^a   Borgen, Katrine ^a   Hungnes, Olav ^a   Dudman, Susanne G ^a   Aavitsland, Preben ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b Norwegian Field Epidemiology Training Programme   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; ZANAMIVIR; ANTIVIRUS AGENT;

ANTIVIRAL RESISTANCE; ARTICLE; DATA BASE; DRUG MARKETING; FEAR; INFLUENZA VIRUS A H1N1; NONHUMAN; NORWAY; PANDEMIC; COMMERCIAL PHENOMENA; DRUG EFFECT; HUMAN; INFLUENZA; PHYSIOLOGY; STATISTICS; VIROLOGY;

INFLUENZA A VIRUS;

ANTIVIRAL AGENTS; COMMERCE; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; NORWAY; OSELTAMIVIR;

EID: 66249104364     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-6-54     Document Type: Article

References (11)

1. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. A Lackenby O Hungnes SG Dudman A Meijer WJ Paget AJ Hay MC Zambon, Euro Surveillance: Bulletin Europeen sur les Maladies Transmissibles = European Communicable Disease Bulletin 2008 13 18445375
2. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. SH Hauge S Dudman K Borgen A Lackenby O Hungnes, Emerging Infectious Diseases 2009 15 155 162 19193257 10.3201/eid1502.081031
3. Influenza A(H1N1) virus resistance to oseltamivir, last quarter 2007 to June 2008 (Uptdate 13 June 2008). http://www.who.int/csr/disease/influenza/ oseltamivir-summary/en/index.html
4. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. VP Mishin FG Hayden LV Gubareva, Antimicrobial Agents & Chemotherapy 2005 49 4515 4520 10.1128/AAC.49.11.4515-4520.2005
5. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors. V Escuret E Frobert M Bouscambert-Duchamp M Sabatier I Grog M Valette B Lina F Morfin O Ferraris, Journal of Clinical Virology 2008 41 25 28 10.1016/j.jcv.2007.10.019 18055253
6. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. ML Herlocher R Truscon S Elias HL Yen NA Roberts SE Ohmit AS Monto, Journal of Infectious Diseases 2004 190 1627 1630 10.1086/424572 15478068
7. WHO Guidelines on the Use of Vaccines and Antivirals during Influenza Pandemics. http://www.who.int/csr/resources/publications/influenza/WHO-CDS-CSR- RMD-2004-8/en/
8. Tamiflu SPC [in Norwegian]. http://www.legemiddelverket.no/spc
9. Influenza activity in Norway. http://www.fhi.no/eway/default.aspx?pid= 238&trg=MainArea-5811&MainArea-5811=5895:0:15,2820:1:0:0:::0:0
10. Oseltamivir prescribing in pharmacy-benefits database, United States, 2004-2005. JR Ortiz L Kamimoto RE Aubert J Yao DK Shay JS Bresee RS Epstein, Emerging Infectious Diseases 2008 14 1280 1283 18680656 10.3201/eid1408.080074
11. Correct use of antiviral drugs against influenza. http://www.fhi.no/eway/ default.aspx?pid=233&trg=MainLeft-5670&MainArea-5661=5670:0:15,3403:1:0: 0:::0:0&MainLeft-5670=5544:55408::1:5675:1:::0:0